Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the metrics that really move Joint Corp—clinic count growth, franchise royalties, or membership churn? This page brings every SEC disclosure together so you can stop hunting and start understanding. Whether you need the Joint Corp insider trading Form 4 transactions or the latest Joint Corp quarterly earnings report 10-Q filing, Stock Titan delivers them the moment they hit EDGAR.
Our AI engine reads each document line-by-line and serves plain-English answers. Think of it as "Joint Corp SEC filings explained simply"—from a 300-page 10-K to a one-page 8-K. Click any filing type below and you’ll see auto-generated key points, ratio calculations, and trend charts:
- Joint Corp annual report 10-K simplified—franchise economics, clinic openings, risk factors
- Joint Corp Form 4 insider transactions real-time—alerts on executive buys and sells
- Joint Corp proxy statement executive compensation—bonus targets tied to same-store sales
- Joint Corp 8-K material events explained—new market entries or leadership updates
Need deeper context? Our "understanding Joint Corp SEC documents with AI" module cross-links sections so you can compare revenue per clinic across multiple quarters. For quick takeaways, the "Joint Corp earnings report filing analysis" highlights margin shifts and patient visit growth. Professionals monitoring Joint Corp executive stock transactions Form 4 can set real-time alerts to spot patterns before the market reacts.
Every document, every detail, always current—because informed decisions start with complete, clear data.
Joint (NASDAQ:JYNT) agreed to sell the assets of 31 company-owned clinics in Arizona and New Mexico to Joint Ventures, LLC for $11.07 million, with closing targeted on or before 30 Jun 2025 and customary conditions attached. In return, the company will obtain regional developer rights covering 46 existing franchised clinics and 30 future development sites across Northern California, Utah, Nevada, Washington and Oregon, enlarging its franchise pipeline.
In a separate transaction, the company divested five clinics in Kansas and Missouri to 93 Chiro, LLC. Management positions both deals as part of a strategic shift toward an asset-light, royalty-driven model that increases liquidity, cuts operating costs and accelerates unit growth.
FAQ
What is the current stock price of Joint (JYNT)?
What is the market cap of Joint (JYNT)?
What is Joint Corp's core business model?
How does Joint Corp make chiropractic care accessible?
What services do Joint Corp clinics offer?
How does the franchising model contribute to Joint Corp’s growth?
What distinguishes Joint Corp from its competitors?
How is quality patient care ensured at Joint Corp?
What are the primary operational segments of Joint Corp?
How does Joint Corp integrate innovation into its operations?
